I am proud to announce that we have just added a new member to our executive team. We have appointed David Jobes to the position of Senior Vice President of Business and Corporate Development. We would like to welcome Dave to the team. He brings with him a great depth of knowledge and experience and I am confident that he will make a great addition to our growing team.

Numerate, Inc., a technology platform company that is leveraging proprietary algorithms and the power of cloud computing to transform the drug design process, announced today that David Jobes, Ph.D., has joined the company as senior vice president of business and corporate development.

Dr. Jobes brings over 10 years of biopharmaceutical industry experience to Numerate from such diverse areas as diagnostics, vaccines, and small molecule therapeutics. Prior to joining Numerate, he successfully headed his own consulting firm focused on assisting clients with transactional work and business development strategies. Previously, he was co-founder and vice president of business development at Presidio Pharmaceuticals, a small molecule antiviral company. Dr. Jobes also served in various research and leadership roles at VaxGen, Applied Biosystems, and the National Institutes of Health (NIH).

“We are very pleased to welcome Dave to the executive management team at Numerate,” stated Guido Lanza, chief executive officer of Numerate. “His depth of experience in the biotech industry and record of deal making is a major benefit as we continue to expand our corporate partnerships beyond the big pharma relationships we currently have in place.”

“This is an exciting time to be joining Numerate,” commented Dr. Jobes. “It is with technologies like Numerate’s that we will finally begin to regain control of the spiraling time, money and resource costs currently required for generating a small molecule lead. Numerate’s proprietary strategy of combining medicinal chemistry, statistics and computer science, driven by state-of-the-art cloud computing, should help revolutionize the way companies design and discover novel, patentable small molecules.”